



HAL
open science

Rubella vaccine–induced granulomas are a novel phenotype with incomplete penetrance of genetic defects in cytotoxicity

Miriam Gross, Carsten Speckmann, Annette May, Tania Gajardo-Carrasco, Katharina Wustrau, Sarah Lena Maier, Marcus Panning, Daniela Huzly, Abbas Agaimy, Yenan Bryceson, et al.

► **To cite this version:**

Miriam Gross, Carsten Speckmann, Annette May, Tania Gajardo-Carrasco, Katharina Wustrau, et al.. Rubella vaccine–induced granulomas are a novel phenotype with incomplete penetrance of genetic defects in cytotoxicity. *Journal of Allergy and Clinical Immunology*, In press, <10.1016/j.jaci.2021.05.007>. <hal-03432275>

HAL Id: hal-03432275

<https://hal.science/hal-03432275v1>

Submitted on 17 Nov 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

1 **Rubella vaccine-induced granulomas are a novel phenotype with**
2 **incomplete penetrance of genetic defects in cytotoxicity**

3 Miriam Groß, MSc^{1,2}, Carsten Speckmann, MD^{1,3}, Annette May, MD⁴, Tania Gajardo-
4 Carrasco, MSc^{5,6}, Katharina Wustrau, MD⁷, Sarah Lena Maier, MD⁷, Marcus Panning,
5 MD⁸, Daniela Huzly, MD⁸, Abbas Agaimy, MD⁹, Yenan T. Bryceson, PhD^{10,11}, Sharon
6 Choo, MD¹², CW Chow, MD¹³, Gregor Dückers, MD¹⁴, Anders Fasth, MD, PhD¹⁵,
7 Sylvie Fraitag, MD¹⁶, Katja Gräwe, MTA¹, Sabine Haxelmans, TA¹⁷, Dirk Holzinger,
8 MD¹⁸, Ole Hudowenz, MD¹⁹, Judith Hübschen, PhD²⁰, Claudia Khurana, MD²¹,
9 Korbinian Kienle, PhD²², Roman Klifa, MD²³, Klaus Korn, MD²⁴, Heinz Kutzner MD²⁵,
10 Tim Lämmermann, PhD²², Svea Ledig, MD⁷, Dan Lipsker, MD²⁶, Marie Meeths, MD,
11 PhD^{27,28,29}, Nora Naumann-Bartsch, MD³⁰, Jelena Rascon, MD, PhD^{31,32}, Anne
12 Schänzer, MD³³, Maximilian Seidl, MD^{4,34}, Bianca Tesi, MD, PhD^{28,35}, Christelle
13 Vauloup-Fellous, MD³⁶, Beate Vollmer-Kary, TA⁴, Klaus Warnatz, MD^{37,38}, Claudia
14 Wehr, MD^{39,38}, Bénédicte Neven, MD, PhD^{40,41}, Pablo Vargas, PhD⁴², Fernando E.
15 Sepulveda, PhD^{5,6,43}, Kai Lehmborg, MD⁷, Annette Schmitt-Gräff, MD⁴⁴, Stephan Ehl,
16 MD¹

17

18 1 Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Faculty of
19 Medicine, University Medical Center Freiburg, Freiburg, Germany

20 2 Faculty of Biology, University of Freiburg, Freiburg, Germany

21 3 Center for Pediatrics and Adolescent Medicine, Medical Center, Faculty of
22 Medicine, University of Freiburg, Freiburg, Germany

23 4 Institute for Surgical Pathology, Medical Center - University of Freiburg, Freiburg,
24 Germany

- 25 5 Molecular basis of altered immune homeostasis laboratory, INSERM UMR1163,
26 Paris, France
- 27 6 Université de Paris, Imagine Institute, F-75015, Paris France
- 28 7 Division of Pediatric Stem Cell Transplantation and Immunology, University Medical
29 Center Hamburg Eppendorf, Germany
- 30 8 Institute of Virology, Freiburg University Medical Center, Faculty of Medicine,
31 University of Freiburg, Freiburg, Germany
- 32 9 Institute of Pathology, Friedrich Alexander University Erlangen-Nürnberg,
33 University Hospital, Erlangen, Germany
- 34 10 Department of Medicine, Center for Hematology and Regenerative Medicine,
35 Karolinska Institutet, Stockholm, Sweden
- 36 11 Broegelmann Research Laboratory, Department of Clinical Sciences, University of
37 Bergen, Bergen, Norway
- 38 12 Department of Allergy and Immunology, The Royal Children's Hospital,
39 Melbourne, VIC, Australia
- 40 13 Department of Anatomical Pathology, Royal Children's Hospital, Melbourne,
41 Australia
- 42 14 Helios Klinikum Krefeld, Zentrum für Kinder- und Jugendmedizin
- 43 15 Dept of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy University
44 of Gothenburg, Sweden
- 45 16 Department of Pathology, Necker-Enfants Malades Hospital, Paris, France
- 46 17 Life Imaging Center (LIC), University of Freiburg, Germany
- 47 18 Department of Pediatric Hematology-Oncology, University of Duisburg-Essen,
48 Essen, Germany
- 49 19 Department of Rheumatology, Immunology, Osteology and Physical Medicine,
50 Campus Kerckhoff of Justus-Liebig-University Giessen, Bad Nauheim, Germany

- 51 20 World Health Organization European Regional Reference Laboratory for Measles
52 and Rubella, Luxembourg Institute of Health, Department of Infection and Immunity,
53 Esch-sur-Alzette, Luxembourg
- 54 21 Department of Pediatric Hematology and Oncology, Children's Center Bethel,
55 University Hospital OWL / University Bielefeld, Germany
- 56 22 Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany
- 57 23 Immunology and Pediatric Hematology Department, Assistance Publique-
58 Hôpitaux de Paris, Paris, France
- 59 24 Institute of Virology, University Hospital Erlangen, Friedrich-Alexander-University
60 Erlangen-Nürnberg (FAU), Erlangen, Germany
- 61 25 Dermatopathology, Friedrichshafen, Germany
- 62 26 Faculté de Médecine, Université de Strasbourg and Clinique Dermatologique,
63 Hôpitaux Universitaires, Strasbourg
- 64 27 Childhood Cancer Research Unit, Department of Women's and Children's Health,
65 Karolinska Institutet, Stockholm, Sweden.
- 66 28 Department of Molecular Medicine and Surgery, Center for Molecular Medicine,
67 Karolinska Institutet, Stockholm, Sweden
- 68 29 Theme of Children's Health, Karolinska University Hospital, Stockholm, Sweden.
- 69 30 Division of Pediatric Hematology and Oncology, Department of Pediatrics,
70 University Hospital Erlangen, Erlangen, Germany
- 71 31 Center for Pediatric Oncology and Hematology, Vilnius University Hospital
72 Santaros Klinikos, Vilnius, Lithuania
- 73 32 Faculty of Medicine, Vilnius University, Vilnius, Lithuania
- 74 33 Institute of Neuropathology, Justus Liebig University Giessen, Giessen, Germany
- 75 34 Institute of Pathology, Heinrich Heine University and University Hospital of
76 Duesseldorf, Duesseldorf, Germany

- 77 35 Department of Clinical Genetics, Karolinska University Laboratory, Karolinska
78 University Hospital, Stockholm, Sweden.
- 79 36 AP-HP, Hôpital Paul-Brousse, Department of Virology, WHO Rubella National
80 Reference Laboratory, Groupe de Recherche sur les Infections pendant la
81 Grossesse (GRIG), University Paris Saclay, INSERM U1193, 94804 Villejuif, France
- 82 37 Department of Rheumatology and Clinical Immunology, Faculty of Medicine,
83 University Medical Center Freiburg, Freiburg, Germany
- 84 38 Center for Chronic Immunodeficiency, Faculty of Medicine, University Medical
85 Center Freiburg, Freiburg, Germany
- 86 39 Department of Medicine I, Medical Center – University of Freiburg, Faculty of
87 Medicine, University of Freiburg, Germany
- 88 40 Pediatric Hematology-Immunology and Rheumatology Department, Hôpital
89 Necker-Enfants Malades, AP-HP Centre Université de Paris, Paris, France
- 90 41 Université de Paris, Imagine Institute, Laboratory of Immunogenetics of Pediatric
91 Autoimmunity, INSERM UMR 1163, Paris, France
- 92 42 Institut Curie, PSL Research University, CNRS UMR 144 and Institut Pierre-Gilles
93 de Gennes, PSL Research University, Paris, France; INSERM U932 Immunité et
94 Cancer, Institut Curie, PSL Research University, Paris, France
- 95 43 Centre national de la recherche scientifique – CNRS
- 96 44 University of Freiburg, Freiburg, Germany
- 97
- 98

99 **Corresponding author:**

100 Prof. Dr. Stephan Ehl

101 Institute for Immunodeficiency, University Medical Center Freiburg

102 Breisacher Strasse 115, 79104 Freiburg

103 Phone: +49-761-270-77300

104 Fax: +49-761-270-77744

105 stephan.ehl@uniklinik-freiburg.de

106

107 **Funding**

108 MG, AM, KG, BVK, ASG and SE were supported by the Deutsche

109 Forschungsgemeinschaft (SFB1160, TP A1 and Z1). This work was further

110 supported by the Deutsche Kinderkrebsstiftung (DKS 2016.04 and DKS 2018.11).

111 TGC was supported by the French State funding from the Agence Nationale de la

112 Recherche under "Investissements d'avenir" program (ANR-10-IAHU-01) and the

113 "Fondation Bettencourt Schueller".

114

115 **Disclosure of potential conflict of interest**

116 SE received a research grant from UCB outside the submitted work. AF received

117 personal fees outside the submitted work from Lipum as member of the advisory board.

118 All other authors have nothing to disclose.

119 **Abstract** (246 words)

120 **Background:** Rubella virus-induced granulomas have been described in patients with
121 various inborn errors of immunity. Most defects impair T-cell immunity, suggesting a
122 critical role of T cells in rubella elimination. However, the molecular mechanism of virus
123 control remains elusive.

124 **Objective:** To understand the defective effector mechanism allowing rubella vaccine
125 virus persistence in granulomas.

126 **Methods:** Starting from an index case with Griscelli syndrome type 2 and rubella skin
127 granulomas, we combined an international survey with a literature search to identify
128 patients with cytotoxicity defects and granuloma. We performed rubella virus
129 immunohistochemistry and PCR and T-cell migration assays.

130 **Results:** We identified 21 patients with various genetically confirmed cytotoxicity
131 defects, who presented with skin and visceral granulomas. Rubella virus was
132 demonstrated in all 12 accessible biopsies. Granuloma onset was typically before age
133 2 years and lesions persisted from months to years. Granulomas were particularly
134 frequent in MUNC13-4 and RAB27A deficiency, where 50% of patients at risk were
135 affected. Although these proteins have also been implicated in lymphocyte migration,
136 3D migration assays revealed no evidence of impaired migration of patient T cells.
137 Notably, patients showed no evidence of reduced control of concomitantly given
138 measles, mumps or varicella live-attenuated vaccine or severe infections with other
139 viruses.

140 **Conclusions:** We identify lymphocyte cytotoxicity as a key effector mechanism for
141 control of rubella vaccine virus, without evidence for its need in control of live measles,
142 mumps or varicella vaccines. Rubella vaccine-induced granulomas are a novel
143 phenotype with incomplete penetrance of genetic disorders of cytotoxicity.

144

145 **Clinical Implications (28 words):**

146 Lymphocyte cytotoxicity is important for control of rubella vaccine virus persistence.

147 Patients with genetic defects of cytotoxicity including albinism syndromes should not
148 be vaccinated with rubella live vaccine.

149

150 **Capsule Summary (35 words).**151 Lymphocyte cytotoxicity is important for control of rubella vaccine without evidence for
152 its need to control concomitantly given live vaccines. Rubella vaccine-induced
153 granulomas are a novel phenotype with incomplete penetrance of disorders of
154 cytotoxicity.

155

156 **Key words (up to 10):**157 Cytotoxicity, rubella virus, live vaccine, granuloma, primary immunodeficiency,
158 hemophagocytic lymphohistiocytosis, Griscelli syndrome type 2

159

160 **Abbreviations.**

161 AT – Ataxia telangiectasia

162 CHS – Chédiak-Higashi syndrome

163 CMV - Cytomegalovirus

164 CNS – central nervous system

165 CTL – cytotoxic T lymphocyte

166 DTH – delayed type hypersensitivity

167 EBV – Epstein-Barr virus

168 fHLH – familial hemophagocytic lymphohistiocytosis

- 169 HLH - hemophagocytic lymphohistiocytosis
- 170 HSCT- hematopoietic stem cell transplantation
- 171 IEI - inborn errors of immunity
- 172 GS2 – Griscelli syndrome type 2
- 173 LCMV - lymphocytic choriomeningitis virus
- 174 MMR(V) – measles, mumps, rubella, (varicella) live-attenuated vaccine
- 175 PBMCs - Peripheral blood mononuclear cells
- 176 PCR – polymerase chain reaction
- 177 PID – primary immunodeficiency
- 178 RV – rubella virus
- 179 RV-C - rubella virus capsid
- 180 VZV- varicella-zoster virus

181 **Introduction**

182 Perforin-mediated target cell lysis is a key effector mechanism of CD8+ T cells and NK
183 cells. A key function ascribed to cytotoxicity is the control of viral infections by
184 elimination of virus-infected cells (1). This was first documented in perforin-deficient
185 mice that fail to control infection with lymphocytic choriomeningitis virus (LCMV) (2).
186 Patients with genetically impaired perforin-mediated cytotoxicity (including patients
187 with familial hemophagocytic lymphohistiocytosis FHL2-5, Griscelli syndrome type 2,
188 GS2, and Chédiak-Higashi syndrome, CHS) are predisposed to develop the hyper-
189 inflammatory syndrome of familial hemophagocytic lymphohistiocytosis (fHLH) (3).
190 Disease onset can be associated with viral infections (4) and in particular uncontrolled
191 infection with Epstein-Barr virus (EBV) is observed in some fHLH patients. However,
192 in the context of acute fHLH it is difficult to separate whether disease severity reflects
193 lack of antiviral function or rather impaired control of immune stimulation by failure to
194 eliminate antigen-presenting cells (5). Notably, in the majority of infants with the most
195 severe forms of the disease, no viral trigger can be identified (6). There are no reports
196 on live vaccine persistence in fHLH patients. Moreover, uncontrolled viral infection is
197 not a general phenotype of fHLH patients, even when they are not transplanted in the
198 first 2-3 years of life (7). Thus, from a biological point of view, the role of cytotoxicity in
199 the control of many human viruses is not so evident.

200 Granulomas are organized structures formed by macrophages and other immune cells
201 that participate in antimicrobial defense by preventing spread of a persistent pathogen
202 (8). This also includes viral infections such as measles and EBV (9). Recently, elegant
203 work has demonstrated persistence of rubella virus (RV) vaccine strain RA27/3 in skin
204 and visceral granulomas of patients with inborn errors of immunity (IEI) over decades
205 (10–12). Most commonly, these RV associated granulomas were detected in patients
206 with Ataxia-telangiectasia (AT) and other DNA repair disorders, followed by patients

207 with various combined immunodeficiencies (13). The T-cell lymphopenia in most of
208 these patients in combination with evidence of cytotoxic T lymphocyte (CTL) epitope
209 escape mutations in the viral genome (14) suggests a key role for CTL in limiting the
210 observed RV persistence in M2 macrophages (12). Since CD8 T cells predominate
211 around the granulomas, it has been suggested that beyond an initial numeric T-cell
212 deficiency allowing prolonged RV replication, functional impairments such as T-cell
213 exhaustion contribute to RV persistence (13). However, the molecular mechanisms
214 that are essential for rubella vaccine virus control remain incompletely understood.

215 Here we describe a cohort of patients with hereditary cytotoxicity defects, who
216 presented with rubella virus-containing skin and visceral granulomas. There was no
217 evidence that these patients lacked control of concomitantly given measles, mumps or
218 varicella virus or had generally increased susceptibility to viral infections apart from
219 EBV in the context of HLH. Clinically, these observations identify rubella-induced
220 granulomas as a novel phenotype with incomplete penetrance of patients with genetic
221 defects of cytotoxicity. From a biological point of view, they support the concept that
222 lymphocyte cytotoxicity is not needed as effector mechanism against viruses in
223 general, but rather has a selective role against some specific viruses.

224 **Materials and Methods**

225 **Patient Recruitment**

226 Patients with cutaneous granulomas and cytotoxicity defects (“granuloma cohort”) were identified via literature search (PubMed search terms: haemophagocytic lymphohistiocytosis / HLH / disease name / gene name AND granuloma / skin / cutaneous) and the databases from the German HLH Reference Centers Freiburg and Hamburg. Additional cases were identified through our international network of colleagues from the European Society for Immunodeficiencies (ESID), the Inborn Errors Working Party and the Histiocyte Society. Patients were included based on the following criteria: (i) diagnosis of FHL, CHS or GS2 (clinical in 1 GS2 patient, genetic all other patients) (ii) description of skin lesions consistent with granulomas in the patient files (described as: papular, pustular, maculopapular, granulomatous), and – available in all but 1 patient (iii) photographs of the skin lesions, histology, rubella immunohistochemistry or PCR consistent with the diagnosis.

238 An additional, partly overlapping “at risk cohort” comprises patients documented in the German HLH Study between 01/1997 and 06/2020 with genetically confirmed cytotoxicity defects. This study captures more than 80% of such patients manifesting in Germany. We included all patients with a minimum age of 18 months before onset of HLH and/or HSCT to restrict the analysis to patients with likely vaccine exposure. Patients who were known not to be vaccinated against rubella or had a negative serology for MMR were excluded. For patients with unknown vaccination status, vaccination against rubella was presumed based on the high MMR vaccination rate in Germany (15).

247 The research protocol was approved by the Ethics committee, University of Freiburg (EK No. 159/19). All patients in the German HLH study gave informed consent.

249 **Immunohistochemistry**

250 For detection of the rubella virus in patient biopsies, tissue sections were cut from
251 formalin-fixed, paraffin-embedded tissue samples and used for subsequent
252 immunohistochemical analysis. The presence of the viral capsid was visualized by
253 chromogenic or fluorescent detection using the mouse monoclonal anti-rubella virus
254 capsid antibody (clone 9B11, 1:500, Abcam). Tissue sections from sarcoidosis patients
255 were used as negative controls. Staining results were interpreted by an experienced
256 pathologist, based on staining intensity, tissue location of the RV-positive signal and
257 the infected cell type. Further details are provided in the supplementary material.

258 **Molecular Analysis**

259 Frozen skin samples were used to extract RNA for subsequent real-time RT-PCR for
260 rubella virus according to standards of practice.

261 **Cell Culture**

262 Peripheral blood mononuclear cells (PBMCs) from patients and healthy controls were
263 isolated from whole blood using ficoll density gradient centrifugation. To generate
264 CD8⁺ T-cell lines, PBMCs were stimulated with PHA (1.25 µg/ml, Remel), IL-2 (1:100,
265 cell culture supernatant from an IL-2 producing cell line) and gamma-irradiated feeder
266 cells (61.8 Gy, pool of allogeneic PBMCs). Cells were sorted for CD8⁺ T cells after the
267 first round of stimulation. Further details are provided in the supplementary material.

268 **Flow Cytometry Based Assays**

269 NK cell and CTL degranulation assays were performed as previously described (16).
270 CXCR3 expression in resting or CXCL11 (100 nM, PeproTech) stimulated CD8⁺ T-cell
271 lines was analyzed by flow cytometry using an anti-CXCR3 antibody (clone # 49801,
272 R&D Systems). Details of the protocol are provided in the supplementary material.

273 T-cell Migration Assays

274 The chemotactic response of CD8⁺ T-lines to CXCL10 (PeproTech) or CXCL12
275 (PeproTech) was analyzed using Transwell® permeable supports for 24 well plates
276 (polycarbonate membrane, 5 µm pores, Corning). Migration in micro-channels was
277 performed as described in previously (17). To assess T-cell migration in complex 3D
278 environment, collagen experiments were performed as previously described (18).
279 Details of the T-cell migration protocols are provided in the supplementary material.

280

281 **Results**

282 **A patient with Griscelli syndrome type 2 and rubella granulomas**

283 A 2-year-old girl from a consanguineous family was referred due to persistence of a
284 generalized, papulo-pustular rash over 6 months. Upon admission, the non-itching,
285 papular lesions were found on arms, legs and face (Figure S1A). The patient had silver-
286 blond hair (Figure S1A), but her medical history did not reveal relevant infections or
287 hospitalizations. Based on characteristic pigment distribution in the hair shaft (Figure
288 S1B) and a defect in NK and T-cell degranulation (Figure S1C), she was given the
289 clinical diagnosis of GS2, which was confirmed by identification of a homozygous
290 splice site mutation in *RAB27A* (c.240-2A>T). A skin biopsy showed necrotizing
291 epithelioid and giant cell granulomas in the dermis (Figure S1D). Cultures were
292 negative for bacteria and fungi and histochemical stainings did not reveal fungal
293 mycelia or acid-fast bacteria. PCR was performed for mycobacteria and viruses
294 including cytomegalovirus, varicella zoster, mumps, measles and, based on recent
295 reports, rubella virus (RV) (10,12). Indeed, only the PCR for RV was positive and
296 subsequent immunohistological stainings showed RV-positive cells in the center of the
297 granulomas (Figure S1D). The extended patient history revealed measles, mumps and
298 rubella (MMR) vaccinations at 15 and 25 months of age. Rubella was not detected in
299 respiratory secretions or blood and the patient had a protective IgG titer against rubella.

300 **Skin and visceral granulomas are common in patients with genetic defects in** 301 **cytotoxicity**

302 While rubella-associated granulomas have been described mostly in IEI patients with
303 defective T-cell immunity, they have so far not been reported in patients with GS2. To
304 address whether *RAB27A* deficiency and potentially other genetic defects in
305 cytotoxicity predispose to rubella granulomas, we combined a literature search with an

306 analysis of the databases of the German HLH reference centers and enquiries through
307 an international network of colleagues. Twenty additional patients with a history of skin
308 or visceral granuloma were identified based on a clinical description given by referring
309 physicians, the medical reports or publications (Table 1). We evaluated three additional
310 criteria to verify the diagnosis in these 20 patients: (i) photo documentation compatible
311 with skin granulomas, (ii) histological confirmation of granulomas and (iii) identification
312 of rubella by immunohistochemistry and/or PCR. We had access to formalin-fixed
313 paraffin embedded skin biopsies from 10 patients (P2,3,6,8,9,12,15,17,18,19) and
314 detected the RV antigen by immunohistochemistry in all samples. Additionally, rubella
315 was identified in 3 of these patients (P1,6,15) by RT-PCR analysis of fresh skin
316 biopsies. Sequence analysis of the PCR products in 2 patients (P6,15) revealed a
317 sequence identical (P6, 131 nt sequenced) or nearly identical (P15, 739 nt sequenced,
318 98.2% alignment) with that of the rubella RA27/3 vaccine strain. Overall, 7/21 patients
319 fulfilled 2 criteria, 3/21 fulfilled 3 criteria and 10/21 fulfilled all 4 criteria (Table 1). In
320 addition to skin granulomas, some patients had rubella-positive extracutaneous
321 granulomas in the liver (P12) or lung (P8,19), detected in the context of liver or
322 interstitial lung disease. P14 only presented with lung granulomas (Table 1). Among
323 the 21 patients in this “granuloma cohort”, 13 had RAB27A deficiency, 5 had MUNC13-
324 4 deficiency, 2 had PRF1 deficiency and 1 had MUNC18-2 deficiency (Table 1).
325 Patients with FHL2 (perforin deficiency), FHL3 (MUNC13-4 deficiency) or FHL5
326 (MUNC18-2 deficiency) had at least one point or splice site mutation (Suppl. Table 1)
327 possibly indicating hypomorphic disease variants.

328 **Clinical and immunohistochemical variability of granulomas**

329 Most patients presented with isolated, non-confluent maculopapular or pustular lesions
330 on arms, legs and face, which in some cases developed into hyperkeratotic papules
331 (P6, P15). However, papules were also found on the trunk or buttocks (P3, P7, P8,

332 P10, P11, P13, P21) (Figure 1), 2 patients only had a single granulomatous lesion on
333 the leg (P17, P19) which gradually increased in size. Overall, clinical manifestations
334 were similar in patients with different cytotoxicity defects (Figure 1, particularly P7, P18
335 and P3, P15). Positive RV immunostaining was found in granulomas in the dermis and
336 granuloma-like histiocytic aggregates in the dermis, lung and liver (Figure 2). The
337 quantity of RV positive cells varied considerably between patients. Whereas in some
338 sections the RV antigen could be detected in many epithelioid cells in the center of
339 granulomas, others only showed a few positive cells. RV-positive cells also stained
340 positive for the macrophage marker CD68 (Figure 2), demonstrating that macrophages
341 were the cell type harboring the virus. Granulomas in the dermis were usually
342 epithelioid and occasionally contained multinucleated giant cells (Figure 2A). Some
343 granulomas also showed central necrosis. Lymphocytic infiltrates (including CD8+ T
344 cells) were located in the periphery of the granulomas (Figure 2A).
345 Hyper(para)keratosis of the epidermis was seen in 5/11 skin samples.

346 **Clinical course of granulomas and response to treatment**

347 The temporal relationship between vaccination, onset and persistence of granulomas
348 is summarized in Table 1 and Figure 3. Patients had received their first MMR dose
349 between 12-52 months of age (median 13.5 M, n = 14) and developed granulomas 4
350 months (median, range 0.5 M – 3 Y, n = 14) later. The median age at granuloma onset
351 was 20 months (n = 18) and preceded HLH development in all 16 patients who
352 eventually developed HLH. Only 4 patients showed HLH symptoms within 3 months
353 after granuloma onset. In P8, *Pseudomonas aeruginosa* superinfection of the skin
354 lesions was a possible trigger of incomplete HLH and in P4 HLH onset was linked to
355 EBV infection. No possible infectious triggers were given for P20 and P21, raising the
356 possibility that the rubella vaccination could have triggered the HLH episode. Apart
357 from EBV-associated HLH in P4, P7, P11, VZV-associated “CNS-only” HLH in P2 and

358 CMV-associated hepatitis in P18, none of the patients were reported to have suffered
359 from severe or unusual courses of viral infections.

360 Skin granulomas persisted over months or even years (range 1.5 M – 6.5 Y, n = 18),
361 but eventually spontaneously resolved with variable residual scars in 7/21 patients.
362 P17 had a single lesion increasing in size over the course of 6.5 years which was
363 excised in total and did not reoccur. Systemic glucocorticoids were associated with
364 improvement of skin lesions in 5/6 patients. In 4 patients (P3, P4, P20, P21), HLH-
365 directed therapy (mostly HLH94) was not associated with deterioration of the
366 granulomas but induced partial or complete remission in P3 and P4. Five patients
367 entered HSCT with skin lesions, which completely resolved in 4 within a few weeks.
368 P3 had resolution of the erythematous component, but atrophic papules persisted and
369 were later surgically excised.

370 **Risk of rubella granuloma varies with genetic diagnosis**

371 To understand how frequently patients with cytotoxicity defects are affected by skin
372 granulomas, we identified 61 patients with genetically confirmed cytotoxicity defects
373 and a minimum age of 18 months before clinical onset of HLH via the databases of the
374 German national HLH study (Figure 4A). In this “at risk cohort” (including 9 patients
375 that were also part of the “granuloma cohort”), rubella vaccination or antibody titers
376 against rubella had been explicitly documented in 43 patients. In the remaining 18
377 patients, rubella vaccination was presumed based on 97% MMR vaccination rates in
378 Germany (15). Patient reports revealed skin lesions consistent with rubella granulomas
379 in 9/61 patients (14.7%) (Figure 4B) and RV could be demonstrated in all 5 accessible
380 biopsies. Skin lesions were described in 1/11 FHL3, 1/14 FHL5 and 7/14 GS2 patients
381 (Figure 4B), but not in patients with CHS, FHL2 or FHL4.

382 **No evidence for impaired T-cell migration in patients with genetic defects of**
383 **lymphocyte cytotoxicity**

384 Literature indicates a role for RAB27A in cell motility (19–22) and GS2 patients were
385 shown to have absent delayed-type cutaneous hypersensitivity (DTH) responses
386 (23,24). Since nearly all patients had deficiency in RAB27A or the RAB27A interaction
387 partner MUNC13-4, we considered that the mutations impair T-cell migration and
388 therefore rubella clearance in the skin.

389 Since the chemokine receptor CXCR3 and its ligands are important for directed
390 migration of T cells and NK cells into inflamed tissues and contribute to virus control in
391 the skin (25–27), we first tested expression and regulation of CXCR3 (Figure 5A).
392 Surface expression of CXCR3 on CD8+ T cells was similar in patient and control cells
393 and stimulation with CXCL11 caused a comparable downregulation and re-expression
394 kinetics of CXCR3. Moreover, patient cells showed concentration-dependent migration
395 towards the chemokine CXCL10 that was comparable with control cells (Figure 5B).
396 To investigate the motility of RAB27A- and MUNC13-4-deficient CD8+ T cells in a more
397 confined environment, we examined the migration of fluorescently labelled T-cell blasts
398 along 4 µm wide micro-channels (Figure 5C). Patient T cells moved at the same speed
399 as control cells. Also, when the skin's dermal layer was mimicked by using a three-
400 dimensional (3D) collagen gel matrix, time-lapse video microscopy revealed no
401 differences in speed between CD8+ T cells from patients and healthy controls (Figure
402 5D). In summary, we could not provide evidence that RAB27A- and MUNC13-4-
403 deficiency affects the spontaneous or chemokine-induced motility of CD8+ T cells.

404

405 **Discussion**

406 Here we show that rubella vaccine-induced granulomas are a novel phenotype with
407 incomplete penetrance in patients with defects of cytotoxicity. This is illustrated by
408 long-term persistence of attenuated rubella vaccine strain in skin and organ
409 granulomas in some, but not all rubella-vaccinated patients with various genetic
410 defects of cytotoxicity.

411 Rubella-associated granulomas are a known complication in IEIs (10–12,28–32). In a
412 series of 66 patients, 17 suffered from AT, 16 from atypical SCID, 25 from various
413 forms of combined immunodeficiencies, 6 patients from CVID and 2 patients from X-
414 linked agammaglobulinemia (13). Apart from the latter two patients, the common
415 theme in all of these diseases are defects in T-cell immunity, in most cases associated
416 with T-cell lymphopenia. We describe here for the first time such lesions in a cohort of
417 patients with normal T-cell numbers, but various defects in lymphocyte cytotoxicity.
418 These observations strongly suggest that cytotoxicity is a key effector mechanism in T
419 cell mediated control of rubella virus. This raises the question, whether impaired
420 cytotoxicity may also contribute to granuloma development in other IEI such as AT.
421 However, there is no evidence that lymphocyte cytotoxicity is impaired in AT patients
422 (33). Moreover, in most AT patients presenting with rubella granulomas, T-cell
423 lymphopenia was documented, suggesting that similar to atypical SCID/CID patients,
424 the numeric T-cell deficiency is a key factor in these diseases.

425 The clinical characteristics of the granulomas in our cohort showed many similarities
426 with those of the published IEI patients. We also observed a time lag between MMR
427 vaccination and granuloma onset of several months to years. We found similar
428 immunohistological characteristics with positive rubella staining of variable extent and
429 not correlating with granuloma severity, located in macrophages within granulomas.

430 Overall, lesions in our patients were less severe than some of those described in
431 published IEI patients. Several patients had only a few non-ulcerated, disseminated
432 nodules or superficial plaques, that spontaneously resolved with variable scar
433 formation without treatment after several months in one third of the cases. However,
434 in the majority of patients, granulomas persisted longer and we also found rubella-
435 antigen in visceral organ granulomas (liver and lung) in 5/21 patients years after
436 vaccination. Notably, the immunosuppressive treatment for HLH in some patients led
437 to partial remission and, as observed previously (32), HSCT performed to treat the
438 underlying genetic defect also cured the granulomas in 4/5 patients. This suggests that
439 the ongoing inflammatory response is an important factor of the tissue pathology and
440 although this is likely to be driven by the virus, the risk of secondary viral dissemination
441 is low.

442 One limitation of our study was that we were able to analyze skin and visceral biopsies
443 for the presence of the rubella virus only in 12/21 patients by immunohistochemistry.
444 However, we could demonstrate viral protein in all of them. In 3 patients we had
445 additional access to fresh biopsies, enabling the detection of RV by RT-PCR in all
446 analyzed patients. For the remaining 9/21 patients, we did not have access to biopsies.
447 However, in an effort to minimize misdiagnosis, we carefully considered their clinical
448 morphology, the histopathological findings and the time of appearance relative to
449 rubella vaccination.

450 Why have skin granulomas so far only rarely been reported in patients with cytotoxicity
451 defects? To address the question, whether granuloma formation was a more common
452 phenomenon, we analyzed an “at risk cohort” of 61 patients with genetically confirmed
453 cytotoxicity defect and documented or likely exposure to the MMR vaccine. Based on
454 this analysis, patients with cytotoxicity defects had at least a 1:7 risk to develop skin

455 granulomas after MMR vaccination. Patients with GS2 had the highest risk with 1:2
456 patients eventually developing granulomas during childhood. This indicates that, as in
457 AT, granuloma development in patients with cytotoxicity defects is a phenotype with
458 partial penetrance. Notably, NK cell degranulation was similar in GS2 patients with or
459 without granulomas, suggesting that so far unknown factors in addition to the impaired
460 cytotoxicity determine whether MMR vaccination results in granuloma formation.
461 These could also include factors associated with the vaccine preparation or site of
462 injection.

463 To further explore why GS2 patients were overrepresented in our cohort, we
464 considered the hypothesis that impaired rubella control in the skin could be attributed
465 in part to a T-cell migration defect. This was based on the observation that patients
466 with RAB27A deficiency lack delayed-type skin hypersensitivity reactions (23,24).
467 Moreover, human T cells with RAB27A deficiency were reported to display decreased
468 chemotaxis towards CXCL12 (19,21) and RAB27A-deficient murine neutrophils show
469 diminished migration *in vitro* and *in vivo* (34). In contrast to these findings, we could
470 not demonstrate decreased chemotaxis towards CXCL12 of RAB27A-deficient or
471 MUNC13-4-deficient CD8⁺ T cells. One explanation for this discrepancy could be the
472 differences in assay setup. Indeed, Franciszkiewicz et al. observed diminished
473 migration towards CXCL12 only after recent TCR activation, which they attributed to
474 disturbed synaptic secretion of CCL5 in RAB27A-deficient cells, which is needed for
475 regulated increase of CXCR4 surface expression (21). Since the collagen fiber network
476 of the dermis imposes significant physical constraints on immune cells, we also tested
477 the motility of patient T cells in microchannels and a more complex 3D collagen gel
478 environment. However, also in these assays we found no evidence of impaired T-cell
479 migration in the absence of RAB27A or MUNC13-4.

480 Importantly, rubella granulomas were not only detected in patients with defects at
481 variable steps of the degranulation machinery but also in patients with perforin
482 deficiency. The common mechanistic basis of these diseases is impairment of
483 lymphocyte cytotoxicity. Given that most other IEI-related granulomas were observed
484 in patients with T-cell deficiencies, it is therefore plausible to assume that T cell
485 mediated cytotoxicity is a key effector mechanism to control rubella infection. Hence,
486 the overrepresentation of patients with GS2, FHL3, FHL5 and some patients with
487 hypomorphic FHL2 may be explained by the fact that the residual cytotoxicity in these
488 patients is sufficient to reach the age of MMR vaccination without HLH manifestation,
489 but insufficient to reliably control rubella virus. In contrast, as shown previously,
490 patients with FHL4 and CHS have a milder impairment of cytotoxicity (35,36) and may
491 therefore be able to control the vaccine.

492 It is notable that all patients with rubella granulomas controlled the concomitantly
493 applied attenuated mumps, measles and in several cases varicella live vaccines
494 without obvious clinical sequelae, as shown also in other IEI associated with rubella
495 granulomas (10,12,14). This is unlikely due to different tissue tropism, since not only
496 rubella virus, but also measles and varicella vaccine virus can be isolated from the skin
497 of immunodeficient patients with vaccine-induced rashes (37,38). Moreover, our
498 patients did not suffer from generally increased susceptibility to severe or recurrent
499 viral infections, although exposure to wild-type viruses is likely to require more active
500 effector functions than challenge with an attenuated live vaccine. A notable exception
501 was EBV, which was implicated as a trigger of HLH in 3/16 patients who eventually
502 developed this disease.

503 Is lymphocyte cytotoxicity maybe not as broadly required for control of viral infections
504 as generally assumed? Doubts about this concept also emerge from murine studies.

505 Perforin-deficient (PKO) mice fail to control infection with lymphocytic choriomeningitis
506 virus (LCMV), murine cytomegalovirus (MCMV), Theiler's Murine Encephalomyelitis or
507 ectromelia virus (39–43). However, apart from these prominent examples, cytotoxicity
508 is redundant for the elimination of a large number of other murine host-specific viruses
509 (pneumonia virus of mice, murine gammaherpesvirus 68, JHMV strain of mouse
510 hepatitis virus) (44–46) and viruses not restricted to mice (Vesicular stomatitis virus,
511 Semliki Forest virus, vaccinia virus, cowpox virus, influenza virus, respiratory syncytial
512 virus, Rotavirus) (39,43,47–49). Thus, our human data support the view that
513 cytotoxicity is not needed as an effector mechanism against viruses in general, but
514 rather has a selective role against a few specific viruses (50), including rubella virus.

515 In summary, we document that patients with cytotoxicity defect are at risk of developing
516 rubella virus containing skin and visceral granulomas after MMR vaccination, but do
517 not seem at risk for developing complications associated with uncontrolled measles,
518 mumps or varicella infection. Skin granulomas can be the presenting manifestation of
519 these genetic defects and they should be considered in the differential diagnosis in
520 young children with persistent granulomas of unknown cause. Importantly, children
521 with known cytotoxicity defects should not be given live MMR vaccines.

522

523 **Acknowledgments**

524 We are grateful to the FREEZE Biobank (A. Nieters) of the Medical Faculty, University
525 of Freiburg and the CCI Advanced Diagnostic Unit (I. Fuchs), Medical Center,
526 University of Freiburg for excellent services.

527 SE wishes to gratefully dedicate this manuscript to Rolf Zinkernagel, Hans Hengartner,
528 Hanspeter Pircher and Peter Aichele from the former Institute for Experimental
529 Immunology, Zürich.

530

531 **References**

- 532 1. Harty JT, Tinnereim AR, White DW. CD8+ T cell effector mechanisms in resistance to
533 infection. *Annu Rev Immunol.* 2000;18(1):275–308.
- 534 2. Kägi D, Ledermann B, Bürki K, Seiler P, Odermatt B, Olsen KJ, et al. Cytotoxicity
535 mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice.
536 *Nature.* 1994 May;369(6475):31–7.
- 537 3. Stepp SE. Perforin Gene Defects in Familial Hemophagocytic Lymphohistiocytosis.
538 *Science.* 1999 Dec 3;286(5446):1957–9.
- 539 4. Brisse E, Wouters CH, Andrei G, Matthys P. How Viruses Contribute to the Pathogenesis
540 of Hemophagocytic Lymphohistiocytosis. *Front Immunol [Internet].* 2017 Sep 7 [cited
541 2017 Nov 10];8. Available from:
542 <http://journal.frontiersin.org/article/10.3389/fimmu.2017.01102/full>
- 543 5. Terrell CE, Jordan MB. Perforin deficiency impairs a critical immunoregulatory loop
544 involving murine CD8+ T cells and dendritic cells. *Blood.* 2013 Jun 27;121(26):5184–91.
- 545 6. Heeg M, Ammann S, Klemann C, Panning M, Falcone V, Hengel H, et al. Is an infectious
546 trigger always required for primary hemophagocytic lymphohistiocytosis? Lessons from
547 in utero and neonatal disease. *Pediatr Blood Cancer.* 2018 Nov;65(11):e27344.
- 548 7. the HLH study of the GPOH, Ammann S, Lehmborg K, zur Stadt U, Klemann C, Bode SFN,
549 et al. Effective Immunological Guidance of Genetic Analyses Including Exome
550 Sequencing in Patients Evaluated for Hemophagocytic Lymphohistiocytosis. *J Clin*
551 *Immunol.* 2017 Nov;37(8):770–80.
- 552 8. Pagán AJ, Ramakrishnan L. The Formation and Function of Granulomas. *Annu Rev*
553 *Immunol.* 2018 Apr 26;36(1):639–65.
- 554 9. Makino K, Takeichi O, Hatori K, Imai K, Ochiai K, Ogiso B. Epstein-Barr Virus Infection in
555 Chronically Inflamed Periapical Granulomas. Pagano JS, editor. *PLOS ONE.* 2015 Apr
556 17;10(4):e0121548.
- 557 10. Bodemer C, Sauvage V, Mahlaoui N, Cheval J, Couderc T, Leclerc-Mercier S, et al. Live
558 rubella virus vaccine long-term persistence as an antigenic trigger of cutaneous
559 granulomas in patients with primary immunodeficiency. *Clin Microbiol Infect.* 2014
560 Oct;20(10):O656–63.
- 561 11. Neven B, Pérot P, Bruneau J, Pasquet M, Ramirez M, Diana J-S, et al. Cutaneous and
562 Visceral Chronic Granulomatous Disease Triggered by a Rubella Virus Vaccine Strain in
563 Children With Primary Immunodeficiencies: Table 1. *Clin Infect Dis.* 2017 Jan
564 1;64(1):83–6.
- 565 12. Perelygina L, Plotkin S, Russo P, Hautala T, Bonilla F, Ochs HD, et al. Rubella persistence
566 in epidermal keratinocytes and granuloma M2 macrophages in patients with primary
567 immunodeficiencies. *J Allergy Clin Immunol.* 2016 Nov;138(5):1436-1439.e11.

- 568 13. Perelygina L, Icenogle J, Sullivan KE. Rubella virus-associated chronic inflammation in
569 primary immunodeficiency diseases. *Curr Opin Allergy Clin Immunol* [Internet]. 2020
570 Oct 9 [cited 2020 Oct 14]; Publish Ahead of Print. Available from:
571 <https://journals.lww.com/10.1097/ACI.0000000000000694>
- 572 14. Perelygina L, Chen M-H, Suppiah S, Adebayo A, Abernathy E, Dorsey M, et al. Infectious
573 vaccine-derived rubella viruses emerge, persist, and evolve in cutaneous granulomas of
574 children with primary immunodeficiencies. *PLoS Pathog*. 2019 Oct;15(10):e1008080.
- 575 15. Robert Koch-Institut. Epidemiologisches Bulletin 18/2019 - Impfquoten bei der
576 Schuleingangsuntersuchung in Deutschland 2017. 2019 May 2 [cited 2020 May 5];
577 Available from:
578 [https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2019/Ausgaben/18_19.pdf?__](https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2019/Ausgaben/18_19.pdf?__blob=publicationFile)
579 [blob=publicationFile](https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2019/Ausgaben/18_19.pdf?__blob=publicationFile)
- 580 16. Bryceson YT, Pende D, Maul-Pavicic A, Gilmour KC, Ufheil H, Vraetz T, et al. A
581 prospective evaluation of degranulation assays in the rapid diagnosis of familial
582 hemophagocytic syndromes. *Blood*. 2012;119(12):2754–2763.
- 583 17. Vargas P, Terriac E, Lennon-Duménil A-M, Piel M. Study of Cell Migration in
584 Microfabricated Channels. *J Vis Exp*. 2014 Feb 21;(84):51099.
- 585 18. Sáez PJ, Barbier L, Attia R, Thiam H-R, Piel M, Vargas P. Leukocyte Migration and
586 Deformation in Collagen Gels and Microfabricated Constrictions. In: Gautreau A, editor.
587 Cell Migration [Internet]. New York, NY: Springer New York; 2018 [cited 2019 May 28].
588 p. 361–73. Available from: http://link.springer.com/10.1007/978-1-4939-7701-7_26
- 589 19. Colvin RA, Means TK, Diefenbach TJ, Moita LF, Friday RP, Sever S, et al. Synaptotagmin-
590 mediated vesicle fusion regulates cell migration. *Nat Immunol*. 2010 Jun;11(6):495–
591 502.
- 592 20. Singh RK, Mizuno K, Wasmeier C, Wavre-Shapton ST, Recchi C, Catz SD, et al. Distinct
593 and opposing roles for Rab27a/Mlph/MyoVa and Rab27b/Munc13-4 in mast cell
594 secretion. *FEBS J*. 2012 Dec;n/a-n/a.
- 595 21. Franciszkiewicz K, Boutet M, Gauthier L, Vergnon I, Peeters K, Duc O, et al. Synaptic
596 Release of CCL5 Storage Vesicles Triggers CXCR4 Surface Expression Promoting CTL
597 Migration in Response to CXCL12. *J Immunol*. 2014 Nov 15;193(10):4952–61.
- 598 22. Capece T, Walling BL, Lim K, Kim K-D, Bae S, Chung H-L, et al. A novel intracellular pool
599 of LFA-1 is critical for asymmetric CD8+ T cell activation and differentiation. *J Cell Biol*.
600 2017 Nov 6;216(11):3817–29.
- 601 23. Griscelli C, Durandy A, Guy-Grand D, Daguillard F, Herzog C, Prunieras M. A syndrome
602 associating partial albinism and immunodeficiency. *Am J Med*. 1978 Oct;65(4):691–702.
- 603 24. Klein C, Philippe N, Le Deist F, Fraitag S, Prost C, Durandy A, et al. Partial albinism with
604 immunodeficiency (Griscelli syndrome). *J Pediatr*. 1994 Dec;125(6 Pt 1):886–95.

- 605 25. Kuo PT, Zeng Z, Salim N, Mattarollo S, Wells JW, Leggatt GR. The Role of CXCR3 and Its
606 Chemokine Ligands in Skin Disease and Cancer. *Front Med*. 2018 Sep 25;5:271.
- 607 26. Metzemaekers M, Vanheule V, Janssens R, Struyf S, Proost P. Overview of the
608 Mechanisms that May Contribute to the Non-Redundant Activities of Interferon-
609 Inducible CXC Chemokine Receptor 3 Ligands. *Front Immunol*. 2018 Jan 15;8:1970.
- 610 27. Hickman HD, Reynoso GV, Ngudiankama BF, Cush SS, Gibbs J, Bennink JR, et al. CXCR3
611 Chemokine Receptor Enables Local CD8+ T Cell Migration for the Destruction of Virus-
612 Infected Cells. *Immunity*. 2015 Mar;42(3):524–37.
- 613 28. Bender NR, Cardwell LA, Siegel D, Sokumbi O. Rubella Vaccine Persistence Within
614 Cutaneous Granulomas in Common Variable Immunodeficiency Disorder: *Am J*
615 *Dermatopathol*. 2020 Jun;42(6):455–7.
- 616 29. Buchbinder D, Hauck F, Albert MH, Rack A, Bakhtiar S, Shcherbina A, et al. Rubella
617 Virus-Associated Cutaneous Granulomatous Disease: a Unique Complication in
618 Immune-Deficient Patients, Not Limited to DNA Repair Disorders. *J Clin Immunol*
619 [Internet]. 2019 Jan 3 [cited 2019 Jan 8]; Available from:
620 <http://link.springer.com/10.1007/s10875-018-0581-0>
- 621 30. Deripapa E, Balashov D, Rodina Y, Laberko A, Myakova N, Davydova NV, et al.
622 Prospective Study of a Cohort of Russian Nijmegen Breakage Syndrome Patients
623 Demonstrating Predictive Value of Low Kappa-Deleting Recombination Excision Circle
624 (KREC) Numbers and Beneficial Effect of Hematopoietic Stem Cell Transplantation
625 (HSCT). *Front Immunol* [Internet]. 2017 Jul 24 [cited 2019 Jan 16];8. Available from:
626 <http://journal.frontiersin.org/article/10.3389/fimmu.2017.00807/full>
- 627 31. Dhossche J, Johnson L, White K, Funk T, Leitenberger S, Perelygina L, et al. Cutaneous
628 Granulomatous Disease With Presence of Rubella Virus in Lesions. *JAMA Dermatol*.
629 2019 Jul 1;155(7):859–61.
- 630 32. Leclerc-Mercier S, Moshous D, Neven B, Mahlaoui N, Martin L, Pellier I, et al. Cutaneous
631 granulomas with primary immunodeficiency in children: a report of 17 new patients
632 and a review of the literature. *J Eur Acad Dermatol Venereol*. 2019 Apr 15;jdv.15568.
- 633 33. Tsuge I, Matsuoka H, Torii S, Okada J, Mizuno T, Matsuoka M, et al. Preservation of
634 natural killer and interleukin-2 activated killer cell activity in ataxia-telangiectasia with T
635 cell deficiency. *J Clin Lab Immunol*. 1987 May;23(1):7–13.
- 636 34. Singh RK, Liao W, Tracey-White D, Recchi C, Tolmachova T, Rankin SM, et al. Rab27a-
637 mediated protease release regulates neutrophil recruitment by allowing uropod
638 detachment. *J Cell Sci*. 2012 Apr 1;125(7):1652–6.
- 639 35. Jessen B, Maul-Pavicic A, Ufheil H, Vraetz T, Enders A, Lehmborg K, et al. Subtle
640 differences in CTL cytotoxicity determine susceptibility to hemophagocytic
641 lymphohistiocytosis in mice and humans with Chediak-Higashi syndrome. *Blood*. 2011
642 Oct 27;118(17):4620–9.

- 643 36. Sepulveda FE, Debeurme F, Ménasché G, Kurowska M, Côte M, Pachlopnik Schmid J, et
644 al. Distinct severity of HLH in both human and murine mutants with complete loss of
645 cytotoxic effector PRF1, RAB27A, and STX11. *Blood*. 2013 Jan 24;121(4):595–603.
- 646 37. Farnaes L, Coufal NG, Spector SA. Vaccine Strain Varicella Infection in an Infant With
647 Previously Undiagnosed Perinatal Human Immunodeficiency Type-1 Infection: *Pediatr*
648 *Infect Dis J*. 2019 Apr;38(4):413–5.
- 649 38. Iroh Tam P-Y, Hanisch BR, Klammer K, DeVries AS. Measles Vaccine Strain From the Skin
650 Rash of a DiGeorge Patient Receiving Tumor Necrosis Factor Inhibitor: *Pediatr Infect Dis*
651 *J*. 2014 Jan;33(1):117.
- 652 39. Kägi D, Seiler P, Pavlovic J, Ledermann B, Bürki K, Zinkernagel RM, et al. The roles of
653 perforin-and Fas-dependent cytotoxicity in protection against cytopathic and
654 noncytopathic viruses. *Eur J Immunol*. 1995;25(12):3256–3262.
- 655 40. Dix RD, Podack ER, Cousins SW. Loss of the Perforin Cytotoxic Pathway Predisposes
656 Mice to Experimental Cytomegalovirus Retinitis. *J Virol*. 2003 Mar 15;77(6):3402–8.
- 657 41. Gather R, Aichele P, Goos N, Rohr J, Pircher H, Kögl T, et al. Trigger-dependent
658 differences determine therapeutic outcome in murine primary hemophagocytic
659 lymphohistiocytosis. *Eur J Immunol* [Internet]. 2020 Jun 2 [cited 2020 Oct 15]; Available
660 from: <https://onlinelibrary.wiley.com/doi/abs/10.1002/eji.201948123>
- 661 42. Rossi CP, McAllister A, Tanguy M, Kägi D, Brahic M. Theiler's virus infection of perforin-
662 deficient mice. *J Virol*. 1998;72(5):4515–4519.
- 663 43. Müllbacher A, Hla RT, Museteanu C, Simon MM. Perforin is essential for control of
664 ectromelia virus but not related poxviruses in mice. *J Virol*. 1999;73(2):1665–1667.
- 665 44. Allen DJ, Brooks JW, Cardin RD, Doherty PC, Sarawar SR, Nash AA, et al. Immunological
666 control of murine gammaherpesvirus infection is independent of perforin. *J Gen Virol*.
667 1997 Aug 1;78(8):2025–30.
- 668 45. Frey S, Krempf CD, Schmitt-Gräff A, Ehl S. Role of T Cells in Virus Control and Disease
669 after Infection with Pneumonia Virus of Mice. *J Virol*. 2008 Dec 1;82(23):11619–27.
- 670 46. Lin MT, Stohlman SA, Hinton DR. Mouse hepatitis virus is cleared from the central
671 nervous systems of mice lacking perforin-mediated cytotoxicity. *J Virol*. 1997;71(1):383–
672 91.
- 673 47. Aung S, Rutigliano JA, Graham BS. Alternative Mechanisms of Respiratory Syncytial
674 Virus Clearance in Perforin Knockout Mice Lead to Enhanced Disease. *J Virol*. 2001 Oct
675 15;75(20):9918–24.
- 676 48. Franco MA, Tin C, Rott LS, Vancott JL, Mcghee JR, Greenberg HB. Evidence for CD8+ T-
677 Cell Immunity to Murine Rotavirus in the Absence of Perforin, Fas, and Gamma
678 Interferon. *J VIROL*. 1997;71:8.

- 679 49. Kägi D, Ledermann B, Bürki K, Zinkernagel RM, Hengartner H. Molecular mechanisms of
680 lymphocyte-mediated cytotoxicity and their role in immunological protection and
681 pathogenesis in vivo. *Annu Rev Immunol.* 1996;14(1):207–232.
- 682 50. Kägi D, Ledermann B, Burki K, Zinkernagel RFM, Hengartner H. Lymphocyte-mediated
683 Cytotoxicity in vitro and in vivo: Mechanisms and Significance. *Immunol Rev.* 1995
684 Aug;146(1):95–115.
- 685 51. Tesi B, Rascon J, Chiang SCC, Burnyete B, Löfstedt A, Fasth A, et al. A RAB27A 5'
686 untranslated region structural variant associated with late-onset hemophagocytic
687 lymphohistiocytosis and normal pigmentation. *J Allergy Clin Immunol* [Internet]. 2018
688 Mar [cited 2018 Apr 13]; Available from:
689 <http://linkinghub.elsevier.com/retrieve/pii/S0091674918303233>
- 690 52. Eyer D, Petiau P, Finck S, Heid E, Grosshans E, Lutz P. [Granulomatous skin lesions in
691 Griscelli disease]. *Ann Dermatol Venereol.* 1998 Oct;125(10):727–8.
- 692 53. Navarrete CL, Aranibar L, Mardones F, Avila R, Velozo L. Cutaneous granulomas in
693 Griscelli type 2 syndrome. *Int J Dermatol.* 2016 Jul;55(7):804–5.
- 694 54. Gotesman R, Ramien M, Armour CM, Pham-Huy A, Kirshen C. Cutaneous granulomas as
695 the presenting manifestation of Griscelli syndrome type 2. *Pediatr Dermatol* [Internet].
696 2020 Sep 23 [cited 2020 Oct 5]; Available from:
697 <https://onlinelibrary.wiley.com/doi/10.1111/pde.14370>
- 698 55. Murphy MJ. Necrotizing palisaded granulomatous dermatitis as a manifestation of
699 familial hemophagocytic lymphohistiocytosis. *J Cutan Pathol.* 2009 Nov 9;37(8):907–10.
- 700 56. Akyol S, Ozcan A, Sekine T, Chiang SCC, Yilmaz E, Karakurkcu M, et al. Different Clinical
701 Presentation of 3 Children With Familial Hemophagocytic Lymphohistiocytosis With 2
702 Novel Mutations. *J Pediatr Hematol Oncol.* 2020 Oct;42(7):e627–9.
- 703 57. Vargas P, Chabaud M, Thiam H-R, Lankar D, Piel M, Lennon-Dumenil A-M. Study of
704 dendritic cell migration using micro-fabrication. *J Immunol Methods.* 2016
705 May;432:30–4.

706 **Tables**707 **Table 1: Clinical Characteristics of Patients with Cytotoxicity Defects and Clinical Granulomas**

Patient	Diagnosis	Age at Vaccination [Months]	Age at granuloma onset	Age at HLH onset	Description of skin alteration*	Extracutaneous granulomas	Consistent Photodocumentation	Granulomas confirmed by histology	Rubella identified	Criteria fulfilled	Identified via
P1	GS2	15 + 25	22 M	no HLH	papulopustular, granulomatous exanthema on limbs and face	N/R	yes	yes	IHC + PCR (skin)	4/4	Index Patient, R
P2	GS2	15 + 72	17 M	no HLH	skin rash, macules evolving into papules on face and limbs	non-specific granulomatous microfoci in CNS	yes	yes	IHC (skin)	4/4	P4 in (51)
P3	GS2	N/A	36 M	4.5 Y	papular, inflammatory lesions on lower limbs, buttocks and cheeks, some ulcerating	N/R	yes	yes	IHC (skin)	4/4	(52)
P4	GS2	12 [§]	12 - 21 M	> 2 M after granuloma onset	multiple red, crusted papules on cheeks and thighs	N/R	yes	yes	N/A	3/4	(53)
P5	GS2	18	24 M	14.5 Y	skin granulomas on arms and legs	N/R	N/A	yes	N/A	2/4	P2 in (51)
P6	GS2	16 + 18	22 M	no HLH	pustules on limbs	N/R	yes	yes	IHC + PCR (skin)	4/4	R
P7	GS2	12	16 M	17.3 Y	pustules on limbs, face, buttocks	N/R	yes	N/A	N/A	2/4	R
P8	GS2	17 + 78	92 M	incomplete HLH (7.8 Y)	skin rash / extensive skin lesions	lung	yes	yes	IHC (skin + lung)	4/4	Lithuania
P9	GS2	12	13 M	8.7 Y	erythematous papules, granulomatous inflammation	N/R	N/A	yes	IHC (skin)	3/4	R
P10	GS2	12	13 M	no HLH	papules on trunk and limbs	N/R	yes	N/A	N/A	2/4	R
P11	GS2	12	14 M	3.1 Y	red papules on face, limbs and buttocks	N/R	N/A	yes	N/A	2/4	R
P12	GS2	N/A	since childhood	no HLH	red papules	liver, muscle	yes	yes	IHC (skin + liver)	4/4	R
P13	GS2	16	16.5 M	5 Y	non-pruritic, erythematous-violaceous papules on cheeks, limbs and buttocks	N/A	yes	yes	N/A	3/4	(54)
P14	FHL2	52	72 M	8 Y (CNS only)	no skin granulomas	lung	N/A	yes	IHC (lung)	2/4	Australia
P15	FHL2	16 - 40	28 - 40 M	8.5 Y	erythematous papular and hyperkeratotic skin lesions on arm and face	N/R	yes	yes	IHC + PCR (skin)	4/4	France
P16	FHL3	N/A	18 M	after granuloma onset	necrotizing palisaded granulomatous dermatitis, small papules on arms and legs	N/R	N/A	yes	N/A	2/4	(55)
P17	FHL3	12 + 22	24 M	incomplete HLH (10 Y)	small granuloma on right upper thigh, increasing in size over time to 4x3 cm	N/R	yes	yes	IHC (skin)	4/4	R
P18	FHL3	12	16 M	3.6 Y	individual purplish papules with some overlying scale on the face, arms and legs	N/R	yes	yes	IHC (skin)	4/4	Australia
P19	FHL3	12	48 M	6 Y	irregular single maculopapular lesion on left calf	lung	yes	yes	IHC (skin + lung)	4/4	Australia
P20	FHL3	N/A	18 M	21 M	dense rash on arms, legs and face	N/A	yes	N/A	N/A	2/4	P1 in (56)
P21	FHL5	N/A	43 M	45 M	erythematous papules on lower limbs and occasionally on belly	N/R	N/A	N/A	N/A	1/4	R

708
709
710

R = German HLH reference centers, patient included in "AT RISK" cohort, *information taken from medical files and letters, § exact age not given in reference, however MMR vaccination is compulsory in Chile and recommended at 12 M

711 *Abbreviations: N/R = not reported, N/A = not available, CNS = central nervous system, GS2 = Griscelli syndrome type 2, FHL = familial hemophagocytic lymphohistiocytosis, IHC =*
712 *immunohistochemistry*
713

714

715 **Figure legends:**

716 **Figure 1: Clinical pictures of cutaneous skin lesions in patients with cytotoxicity**
717 **defects.**

718 **Figure 2: Histopathological findings in patients with rubella-associated**
719 **granulomas. (A)** Skin biopsy of P2 stained with HE, showing multiple dermal
720 epithelioid granulomas and epidermal hyperkeratosis. Double staining with anti-CD68
721 (red) and anti-RV-C (brown) revealed double positive cells, including giant cells, in the
722 center of the granulomas. Anti-CD8 staining showed infiltrating CD8+ T cells in the
723 periphery of the granulomas. Scale bar = 200 μm (left), 20 μm (right). **(B)** Double
724 staining of the lung biopsy of P14. Scale bar = 50 μm (upper), 20 μm (lower). **(C)**
725 Distribution of RV capsid positive cells in skin samples. Positive cells were located
726 within granulomas or loosely formed granuloma-like histiocytic aggregates. Scale bar
727 = 20 μm .

728 **Figure 3: Clinical course of granulomas in patients with cytotoxicity defects.**

729 Time periods during which granulomas were reported are depicted as grey boxes,
730 whereas white boxes (labelled with “?”) indicate that detailed information on granuloma
731 persistence was not available. Age at vaccination is indicated by triangles, age at
732 granuloma onset (if known) is indicated by an arrow, time point of HSCT by a cross.

733 **Figure 4: Risk of granuloma development for patients with cytotoxicity defects.**

734 **(A)** Recruitment scheme for patients in the “AT RISK” cohort. **(B)** Percentage of cases
735 with skin alterations consistent with rubella granulomas, categorized by underlying
736 genetic disorder. **(C)** Activity of NK cells from GS2 patients with (+ gran.) and without
737 (- gran.) granulomas measured by degranulation assay of resting NK cells. ΔCD107a
738 indicates the difference in the fraction of NK cells expressing CD107a under

739 unstimulated and stimulated conditions. Grey shaded area represents normal values
740 (10th percentile of 94 healthy controls). **(D)** Distribution of granuloma cases among
741 patients with different cytotoxicity defects. Left: Patients included in “AT RISK” cohort,
742 right: all patients with clinical granulomas (skin and visceral).

743 **Figure 5: T cell chemotaxis and migration are not affected by mutations in**
744 **RAB27A or UNC13D. (A)** CXCR3 surface expression on CD8+ T cell lines from
745 healthy donors (HD) and patients with mutations in RAB27A, UNC13D or ATM after
746 stimulation with 100 nM CXCL11. Results from 2 individual experiments are
747 summarized on the left (mean +/- SD), representative histograms are shown on the
748 right. **(B)** Transwell migration of CD8+ T-cell lines towards CXCL10 or CXCL12. Each
749 experiment was performed once. **(C)** Scheme of the micro-channel device used to
750 assess cell speed. Cells are loaded in the round loading chamber and from there
751 spontaneously migrate into the micro-channels (upper section). Lower section depicts
752 CD8+ T-cell lines (labelled with Hoechst33342) moving within 4 µm wide micro-
753 channels. Scale bar = 100 µm. Scheme adapted from Vargas et al. 2016 (57). Mean
754 speeds of 3 individual experiments for 3 HD and patients with mutations in PRF1 (n=1),
755 STXBP2 (n=1), RAB27A (n=2), UNC13D (n=3) are shown as individual values, bars
756 represent mean speed of pooled results +/- SD. **(D)** Schematic drawing of the custom-
757 made PDMS chamber loaded with a mixture of cells and collagen (grey lines), adapted
758 from Sáez et al., 2018 (18). Bright field image of CD8+ T-cell lines moving within the
759 3D collagen matrix (3 mg/ml rat tail collagen type I). Cell tracks after 60 min of cell
760 migration are overlaid as colored lines. Scale bar = 200 µm. 120 cells were tracked per
761 experiment, bars represent mean speed of pooled results +/- SD. (C+D) Open circles
762 represent results obtained for T-cell lines derived from patients with skin granulomas.
763 Statistical analysis: Ordinary one-way ANOVA with Dunnett’s multiple comparisons
764 test.

Fig. 1




Fig. 2




Fig. 3




Fig. 4






Fig. 5


A

Chemokine receptor expression and downregulation





B

Chemotaxis of CD8+ T cells



C

Migration in micro-channels



D

Migration in collagen type I

